Free Trial
→ Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever (From Chaikin Analytics) (Ad)tc pixel Free RYZB Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

RayzeBio (RYZB) Competitors

RayzeBio logo
Compare

RYZB vs. DFTX, HYPD, LIAN, PHXM, and ADIL

Should you be buying RayzeBio stock or one of its competitors? The main competitors of RayzeBio include Definium Therapeutics (DFTX), Hyperion DeFi (HYPD), LianBio (LIAN), PHAXIAM Therapeutics (PHXM), and Adial Pharmaceuticals (ADIL). These companies are all part of the "biotechnology" industry.

How does RayzeBio compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and RayzeBio (NASDAQ:RYZB) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

RayzeBio's return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Definium TherapeuticsN/A -82.07% -58.73%
RayzeBio N/A N/A N/A

Definium Therapeutics presently has a consensus target price of $37.92, indicating a potential upside of 71.99%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Definium Therapeutics is more favorable than RayzeBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
3.00
RayzeBio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

27.9% of Definium Therapeutics shares are held by institutional investors. 2.3% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Definium Therapeutics had 6 more articles in the media than RayzeBio. MarketBeat recorded 6 mentions for Definium Therapeutics and 0 mentions for RayzeBio. RayzeBio's average media sentiment score of 0.00 beat Definium Therapeutics' score of -0.19 indicating that RayzeBio is being referred to more favorably in the news media.

Company Overall Sentiment
Definium Therapeutics Neutral
RayzeBio Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Definium TherapeuticsN/AN/A-$183.79M-$2.13N/A
RayzeBioN/AN/A-$68.60MN/AN/A

Summary

Definium Therapeutics beats RayzeBio on 7 of the 11 factors compared between the two stocks.

How does RayzeBio compare to Hyperion DeFi?

RayzeBio (NASDAQ:RYZB) and Hyperion DeFi (NASDAQ:HYPD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

RayzeBio's return on equity of 0.00% beat Hyperion DeFi's return on equity.

Company Net Margins Return on Equity Return on Assets
RayzeBioN/A N/A N/A
Hyperion DeFi N/A -129.97%-92.39%

25.8% of Hyperion DeFi shares are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Hyperion DeFi has higher revenue and earnings than RayzeBio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RayzeBioN/AN/A-$68.60MN/AN/A
Hyperion DeFi$810K53.86-$45.31M-$11.80N/A

In the previous week, Hyperion DeFi had 4 more articles in the media than RayzeBio. MarketBeat recorded 4 mentions for Hyperion DeFi and 0 mentions for RayzeBio. Hyperion DeFi's average media sentiment score of 0.40 beat RayzeBio's score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company Overall Sentiment
RayzeBio Neutral
Hyperion DeFi Neutral

Hyperion DeFi has a consensus price target of $5.88, suggesting a potential upside of 64.57%. Given Hyperion DeFi's stronger consensus rating and higher probable upside, analysts plainly believe Hyperion DeFi is more favorable than RayzeBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RayzeBio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Hyperion DeFi
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.25

Summary

Hyperion DeFi beats RayzeBio on 10 of the 12 factors compared between the two stocks.

How does RayzeBio compare to LianBio?

LianBio (NASDAQ:LIAN) and RayzeBio (NASDAQ:RYZB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

RayzeBio's return on equity of 0.00% beat LianBio's return on equity.

Company Net Margins Return on Equity Return on Assets
LianBioN/A -33.17% -30.19%
RayzeBio N/A N/A N/A

74.8% of LianBio shares are held by institutional investors. 7.6% of LianBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LianBioN/AN/A-$110.29M-$0.81N/A
RayzeBioN/AN/A-$68.60MN/AN/A

In the previous week, LianBio's average media sentiment score of 0.00 equaled RayzeBio'saverage media sentiment score.

Company Overall Sentiment
LianBio Neutral
RayzeBio Neutral

Summary

RayzeBio beats LianBio on 3 of the 5 factors compared between the two stocks.

How does RayzeBio compare to PHAXIAM Therapeutics?

RayzeBio (NASDAQ:RYZB) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RayzeBioN/AN/A-$68.60MN/AN/A
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A

Company Net Margins Return on Equity Return on Assets
RayzeBioN/A N/A N/A
PHAXIAM Therapeutics N/A N/A N/A

In the previous week, RayzeBio's average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.

Company Overall Sentiment
RayzeBio Neutral
PHAXIAM Therapeutics Neutral

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

PHAXIAM Therapeutics beats RayzeBio on 3 of the 3 factors compared between the two stocks.

How does RayzeBio compare to Adial Pharmaceuticals?

Adial Pharmaceuticals (NASDAQ:ADIL) and RayzeBio (NASDAQ:RYZB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adial PharmaceuticalsN/AN/A-$7.98M-$18.75N/A
RayzeBioN/AN/A-$68.60MN/AN/A

16.4% of Adial Pharmaceuticals shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

RayzeBio's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Adial PharmaceuticalsN/A -182.34% -141.27%
RayzeBio N/A N/A N/A

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than RayzeBio. MarketBeat recorded 1 mentions for Adial Pharmaceuticals and 0 mentions for RayzeBio. Adial Pharmaceuticals' average media sentiment score of 0.00 equaled RayzeBio'saverage media sentiment score.

Company Overall Sentiment
Adial Pharmaceuticals Neutral
RayzeBio Neutral

Adial Pharmaceuticals currently has a consensus price target of $22.75, indicating a potential upside of 1,486.47%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Adial Pharmaceuticals is more favorable than RayzeBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adial Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
RayzeBio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Adial Pharmaceuticals beats RayzeBio on 7 of the 9 factors compared between the two stocks.

Get RayzeBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for RYZB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYZB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RYZB vs. The Competition

Export
MetricRayzeBioBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$3.74B$454.71M$6.21B$12.25B
Dividend YieldN/A3.86%2.78%5.25%
P/E RatioN/A4.1428.7227.17
Price / SalesN/A7,338.85534.2276.38
Price / CashN/A13.1343.3053.97
Price / BookN/A82.329.916.84
Net Income-$68.60M-$96.07M$3.55B$333.00M

RayzeBio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RYZB
RayzeBio
N/A$62.49
flat		N/AN/A$3.74BN/AN/A88
DFTX
Definium Therapeutics
3.2436 of 5 stars		$20.98
-6.7%		$38.00
+81.1%		+252.9%$2.24BN/AN/A40
HYPD
Hyperion DeFi
2.8565 of 5 stars		$4.39
+5.3%		$5.88
+33.8%		+233.6%$47.50M$810KN/A40
LIAN
LianBio
N/A$0.12
-1.5%		N/A-27.0%$13.18MN/AN/A110
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat		N/AN/A$10.58MN/AN/A49

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RYZB) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
The Death of the Nasdaq?
The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...
Chaikin Analytics | Sponsoredtc pixel
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...
Eagle Publishing | Sponsoredtc pixel
‘Please’: OpenAI CEO Sam Altman Begs Small Company for Help
SpaceX 'Dark Energy' Replaces Foreign Oil For years, we've been told SpaceX is a rocket company. But accord...
Altimetry | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel